
El-Sadr WM, Lundgren JD, Neaton JD, et al. 

HIV-negative person might. For example, 

high, just as an 

tunistic infections increases monotonically 

CD4 cell counts at death. As CD4 cell 

note that there is substantial variation in 

mortality in people infected with HIV and 

relationships between 

important than the variation in and level 

CD4 cell counts before HIV seroconversion, 

which appear to affect the rate of 

CD4 cell count decline and, hence, the 

survival time after infection. A recent 

study compared CD4 cell counts in HIV- 

negative persons from 7 countries, and 

the medians varied from 599 cells/μL in 

Botswana to 968 cells/μL in Tanzania [8]; the 

authors suggested that CD4 cell count ref 

cence ranges should be established for 

local populations, given the pivotal role 

played by CD4 cell counts in decision 

making on the initiation and monitoring of 

highly active antiretroviral therapy. 

The most important prediction of our 

model is that the distribution of survival 

times is independent of the initial CD4 

cell count, and this prediction is not sub 

stantially altered if we assume a somewhat 

higher CD4 cell count at death. To the 

extent that the prediction is true, it sugg 

ests that, for a given person or group of 

people, survival from a given CD4 cell 

count will be longer for those whose initial 

CD4 cell count is lower than for those in 

whom it is high. More-extensive data and 

more-sophisticated models could provide 

important insights into the relationship 

among CD4 cell count, the progression of 

HIV infection, and mortality, as Lawn and Wood suggest.

Brian G. Williams, 1 Eline L. Korenromp, 2* 

Eleanor Gouws, 3* George P. Schmid, 2* 

Bertran Auvert, 6,7,8 and Christopher Dye 1

1 Stop TB Department and ‘HIV/AIDS Department, 

World Health Organization, ‘The Global Fund to 

Fight AIDS, TB, and Malaria, and ‘Policy, 

Evidence, and Partnerships Department, Joint 

United Nations Program on HIV/AIDS, Geneva, 

Switzerland; ‘Department of Public Health, 

Erasmus Medical Center, University Medical 

Centre Rotterdam, Rotterdam, The Netherlands; 

‘Institut National de la Santé et de la Recherche 

Médicale, Unité 887, and ‘Université de Versailles– 

Saint Quentin, Faculté de Médecine Paris-Ile-de-France-Ouest, Saint Maurice, and ‘APH-HP, 

Hôpital Ambroise Pare, Boulogne, France

References


6. Siíka AM. Predictors of mortality in HIV-in 

fected adult African patients receiving highly active 


Potential conflicts of interest: none reported.

Reprints or correspondence: Dr. Brian G. Williams, World Health Organization, WHO/AC/DSH/STB/TME, 20 Avenue Appia, Geneva 1211, Switzerland (williamsbg@who.int).

The Journal of Infectious Diseases 2007; 195:1078–9 © 2007 by the Infectious Diseases Society of America. All rights reserved. 0022-1899/2007/19507-0024$15.00 DOI: 10.1086/512164

CORRESPONDENCE • JID 2007;195 (1 April) • 1079

Reply to Lawn and Wood

To the Editor—Lawn and Wood [1] raise an important issue concerning the relationship between CD4 cell counts and mortality in people infected with HIV and note that there is substantial variation in CD4 cell counts at death. As CD4 cell counts decline, the incidence of opportunistic infections increases monotonically [2]; if such infections are left untreated, then people may die when their CD4 cell counts are still relatively high, just as an HIV-negative person might. For example, in a comparison of 8 studies, the mean CD4 cell count in HIV-positive patients presenting with tuberculosis was 202 cells/μL (range, 136–269 cells/μL) [3]. If better data on the time course of CD4 cell counts in a sufficiently large sample of HIV-positive patients were available, more-sophisticated models of the relationship between CD4 cell count decline, the incidence of opportunistic infections, and mortality could be developed. Our model, which draws on the limited data that are currently available, is a step in this direction.

It is nevertheless worth noting that evidence from industrialized and low- and middle-income countries suggests that the majority of AIDS-related deaths occur at very low CD4 cell counts. For example, in a study in South Africa in the early 1990s, the median CD4 cell count at the onset of AIDS was 98 cells/μL for heterosexual patients and 40 cells/μL for homosexual patients, after which the median survival time was 17 and 7 months, respectively [4]. In an Australian cohort followed between 1986 and 1991, the median CD4 cell count at death was 10 cells/μL [5]. In Uganda, a recent study showed that the median CD4 cell count at death was 24 cells/μL [6]. In the United Kingdom, a study reported mean CD4 cell counts at death of 19 cells/μL in 1988, 44 cells/μL in 1997, and 58 cells/μL in 1998 [7].

For the purpose of our model, the variation in CD4 cell counts at death is less important than the variation in and level of CD4 cell counts before HIV seroconversion, which appear to affect the rate of CD4 cell count decline and, hence, the survival time after infection. A recent study compared CD4 cell counts in HIV-negative persons from 7 countries, and the medians varied from 599 cells/μL in Botswana to 968 cells/μL in Tanzania [8]; the authors suggested that CD4 cell count reference ranges should be established for local populations, given the pivotal role played by CD4 cell counts in decision making on the initiation and monitoring of highly active antiretroviral therapy.

The most important prediction of our model is that the distribution of survival times is independent of the initial CD4 cell count, and this prediction is not substantively altered if we assume a somewhat higher CD4 cell count at death. To the extent that the prediction is true, it suggests that, for a given person or group of people, survival from a given CD4 cell count will be longer for those whose initial CD4 cell count is lower than for those in whom it is high. More-extensive data and more-sophisticated models could provide important insights into the relationship among CD4 cell count, the progression of